Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlvotechOISE:ALVO 55 EV-to-EBITDA is 12.07 as of Aug. 04, 2026. GuruFocus rates OISE:ALVO with a GF Score™ of 55/100 and a GF Value™ of kr2,344.92 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 746 Drug Manufacturers companies, Alvotech ranks better than 54.42% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alvotech's enterprise value is kr335,326 Mil.
Alvotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr27,785 Mil. Therefore, Alvotech's EV-to-EBITDA for today is 12.07.
The historical rank and industry rank for Alvotech's EV-to-EBITDA or its related term are showing as below:
OISE:ALVO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -155.29 Med: -5.52 Max: 44.54
Current: 11.84
During the past 7 years, the highest EV-to-EBITDA of Alvotech was 44.54. The lowest was -155.29. And the median was -5.52.
OISE:ALVO's EV-to-EBITDA is ranked better than 54.42% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.08
vs OISE:ALVO: 11.84
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alvotech's share price for today is kr475.00.
Alvotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-35.751.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alvotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OISE:ALVO vs PCRX, BIOA, COLL: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alvotech EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alvotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alvotech's EV-to-EBITDA falls into.
Alvotech's current Enterprise Value is kr335,326 Mil.
Alvotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr27,785 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alvotech (OISE:ALVO) has a EV-to-EBITDA of 12.07 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alvotech. According to the industry distribution chart, Alvotech ranks #340 out of 746 companies in the Drug Manufacturers industry, placing it in the top 45.6%.
Is Alvotech's EV-to-EBITDA too high?
Alvotech's current EV-to-EBITDA is 12.07. The Drug Manufacturers industry median EV-to-EBITDA is 13.08. Alvotech's value of 12.07 is 7.7% below this industry median. Based on the distribution chart, Alvotech ranks #340 out of 746 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alvotech has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's EV-to-EBITDA compare to PCRX and BIOA?
According to the Drug Manufacturers industry distribution chart, Alvotech ranks #340 out of 746 companies for EV-to-EBITDA. This puts Alvotech in the upper half of its industry. The industry median EV-to-EBITDA is 13.08. Alvotech's value of 12.07 is 7.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.08, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alvotech's current EV-to-EBITDA of 12.07 is 7.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alvotech. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alvotech's current EV-to-EBITDA is 12.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,344.92, compared to a current price of kr475.00 — trading 79.7% below its estimated fair value. The current EV-to-EBITDA is 12.07 and 7.7% below the Drug Manufacturers industry median of 13.08. Alvotech's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current EV-to-EBITDA is 12.07 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alvotech (OISE:ALVO) Overvalued in 2026?
Based on GuruFocus' analysis, Alvotech stock appears to be undervalued.
The current stock price of kr475.00 is trading 79.7% below its estimated GF Value™ of kr2,344.92.
GuruFocus considers Alvotech to be Possible Value Trap.
Key valuation signals for OISE:ALVO:
EV-to-EBITDA: 12.07
GF Value™: kr2,344.92 vs. price of kr475.00 (79.7% below fair value)
Industry Position: 7.7% below the Drug Manufacturers median (#340 of 746)
No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
55GF Score
Get the complete analysis for OISE:ALVO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OISE:ALVO has been successfully added to your 
